We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+41.28%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$907M
AUM Growth
+$202M
Cap. Flow
-$185K
Cap. Flow %
-0.02%
Top 10 Hldgs %
41.16%
Holding
93
New
10
Increased
12
Reduced
5
Closed
9

Top Buys

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$15.3M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$13.9M
3
KA
Kineta, Inc. Common Stock
KA
+$13.2M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$10.9M
5
MTVA
MetaVia Inc
MTVA
+$10M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$30.5M
2
NKTR icon
Nektar Therapeutics
NKTR
+$28.8M
3
SAGE
Sage Therapeutics
SAGE
+$22M
4
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$18.9M
5
NVAX icon
Novavax
NVAX
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
2 Miscellaneous 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GNVC
76
DELISTED
GenVec, Inc.
GNVC
$468K 0.05%
101,569
-17,496
-15% -$101K
NEOS
77
DELISTED
Neos Therapeutics, Inc
NEOS
$333K 0.04%
50,613
– –
PVCT
78
DELISTED
PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
$221K 0.02%
2,226,961
– –
ONSIW
79
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$199K 0.02%
416,666
– –
ADAP
80
DELISTED
Adaptimmune Therapeutics
ADAP
$178K 0.02%
25,307
– –
AGTC
81
DELISTED
Applied Genetic Technologies Corporation
AGTC
$169K 0.02%
17,321
– –
CLRB icon
82
Cellectar Biosciences
CLRB
$22.2M
$145K 0.02%
18
– –
PVCT.WS
83
DELISTED
PROVECTUS BIOPHARMACEUTICALS INC WTS (DE)
PVCT.WS
$114K 0.01%
2,200,000
– –
CLRBW
84
DELISTED
Cellectar Biosciences, Inc.
CLRBW
$13K ﹤0.01%
52,999
– –
AGIO icon
85
Agios Pharmaceuticals
AGIO
$1.97B
– –
-50,000
Closed -$2.1M
DVAX
86
DELISTED
Dynavax Technologies
DVAX
– –
-635,000
Closed -$9.26M
MCRB icon
87
Seres Therapeutics
MCRB
$42.3M
– –
-12,653
Closed -$7.35M
NKTR icon
88
Nektar Therapeutics
NKTR
$2.3B
– –
-134,859
Closed -$28.8M
NVAX icon
89
Novavax
NVAX
$1.54B
– –
-80,980
Closed -$11.8M
SAGE
90
DELISTED
Sage Therapeutics
SAGE
– –
-730,000
Closed -$22M
TSRO
91
DELISTED
TESARO, Inc.
TSRO
– –
-362,875
Closed -$30.5M
VTAE
92
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
– –
-1,754,795
Closed -$18.9M
RLYP
93
DELISTED
RELYPSA INC COM
RLYP
– –
-450,000
Closed -$8.32M
1 2 3
4

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q3 2016 Portfolio in Review

As of Q3 2016, Cormorant Asset Management held 93 positions worth $907M, up 29% from $705M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Cormorant Asset Management's Q3 2016 filing shows 10 new, 12 increased, 5 reduced and 9 closed positions. Its largest new stake was Clovis Oncology, Inc.: 650,000 shares worth $23.4M. The largest sale was TESARO, Inc., an estimated $30.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier, followed by Miscellaneous.

  • Cormorant Asset Management's largest Q3 2016 buy was Clovis Oncology, Inc.: 650,000 shares worth $23.4M.
  • Cormorant Asset Management added most to MyoKardia, Inc. Common Stock in Q3 2016, an estimated $15.3M increase.
  • Cormorant Asset Management's biggest Q3 2016 reduction was Alnylam Pharmaceuticals, cutting an estimated $5.24M.
  • Cormorant Asset Management fully exited TESARO, Inc. in Q3 2016, selling an estimated $30.5M.
  • Cormorant Asset Management's ten largest holdings make up 41% of its $907M portfolio in Q3 2016.
  • Cormorant Asset Management opened 10 new positions and closed 9 in Q3 2016.
  • Cormorant Asset Management's portfolio value rose 29% quarter-over-quarter to $907M.

Based on Cormorant Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.